The DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
Insight into the Mechanism of a Peptide Inhibitor of HIV Reverse Transcriptase Dimerization
Abstract
The biologically active forms of human immunodeficiency viruses type 1 and 2 reverse transcriptase (RT) found in infectious virions are heterodimers. We have previously shown that the dimeric nature of reverse transcriptase represents an important target for the design of a new class of antiviral agents and have designed a short peptide (Pep-7) derived from the tryptophan-rich motif of the connection subdomain that blocks dimerization of reverse transcriptase in vitro and abolishes viral infection. In the present work, we have investigated the mechanism through which this peptide inhibits RT dimerization and consequently viral propagation. We demonstrate that Pep-7 interacts preferentially with the p51 subunit within the heterodimeric reverse transcriptase, which destabilizes reverse transcriptase dimer conformation, thereby triggering dissociation. We have identified two residues Trp(24) and Phe(61), located on the fingers subdomain of p51, required for Pep-7 binding. Selective mutation of these residues on p51 to a glycine dramatically alters the stability of the RT-heterodimer suggesting that the fingers subdomain of p51 is also involved in stabilization of reverse transcriptase. We propose that the binding site of Pep-7 is located in a cleft between the fingers and the connection subdomains of p51 that contains the two highly conserved residues Phe(61) and Trp(24).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Importantly, nanoparticle-based delivery of a peptide-type dimerization inhibitor to cells resulted in an antiviral submicromolar EC50 [112].”
From Retroviral RNase H: structure, mechanism, and inhibition (2021) · cites this paper as [112]
Citations
Cites
Strategies in the design of antiviral drugs
De Clercq, E. (2002) · Nature Reviews Drug Discovery · doi:10.1038/nrd703 · Cited by 652
Characterization of Highly Immunogenic p66/p51 as the Reverse Transcriptase of HTLV-III/LAV
di Marzo Veronese, F., Copeland, T. D., DeVico, A. L., Rahman, R., Oroszlan, S., Gallo, R. C., & Sarngadharan, M. G. (1986) · Science · doi:10.1126/science.2418504 · Cited by 545
Restle, T., Müller, B., & Goody, R. S. (1990) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)38799-x · Cited by 184
Self-citationDivita, G., Restle, T., Goody, R. S., Chermann, J., & Baillon, J. G. (1994) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)36800-x · Cited by 78
Self-citationDimerization Kinetics of HIV-1 and HIV-2 Reverse Transcriptase: A Two Step Process
Divita, G., Rittinger, K., Geourjon, C., Deléage, G., & Goody, R. S. (1995) · Journal of Molecular Biology · doi:10.1006/jmbi.1994.0042 · Cited by 70
Self-citationRNase H activity of HIV reverse transcriptases is confined exclusively to the dimeric forms
Restle, T., Müller, B., & Goody, R. S. (1992) · FEBS Letters · doi:10.1016/0014-5793(92)80172-d · Cited by 68
Self-citationWöhrl, B. M., Krebs, R., Thrall, S. H., Grice, S. F. J. L., Scheidig, A. J., & Goody, R. S. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.28.17581 · Cited by 66
Role of Residues in the Tryptophan Repeat Motif for HIV-1 Reverse Transcriptase Dimerization
Tachedjian, G., Aronson, H. G., Santos, M. D. L., Seehra, J., McCoy, J. M., & Goff, S. P. (2003) · Journal of Molecular Biology · doi:10.1016/s0022-2836(02)01433-x · Cited by 60
Sluis-Cremer, N., Arion, D., Abram, M. E., & Parniak, M. A. (2004) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2004.02.020 · Cited by 57
Rodríguez‐Barrios, F., Pérez, C., Lobatón, E., Velázquez, S., Chamorro, C., San‐Félix, A., Pérez‐Pérez, M., Camarasa, M., Pelemans, H., Balzarini, J. M., et al. (2001) · Journal of Medicinal Chemistry · doi:10.1021/jm001095i · Cited by 57
Research works printed but not linked: 22
- Richman D. D., 1996, Biol. 394, 383−395.
- Parniak M. A., 2000, Adv. Pharmacol., 49, 109
- Menendez-Arias L., 2002, Trends Pharmacol. Sci. 23, 381−388.
- Kohlstaedt L. A., 1992, Science 256, 1783−1790.
- Jacobo-Molina A., 1993, Proc. Natl. Acad. Sci. U.S.A. 90
- Debyser Z., 1996, Protein Sci. 5, 278−286.
- Divita G., 1995, Biochemistry 34, 16337−16346.
- Tachedjian G., 2000, Proc. Natl. Acad. Sci. U.S.A. 97
- Sluis-Cremer N., 2002, Eur. J. Biochem. 269, 5103−5111.
- Sluis-Cremer N., 2002, Mol. Pharmacol. 62, 398−405.
- Sluis-Cremer N., 2000, Biochemistry 39, 1427−1433.
- Tachedjian G., 2001, Proc. Natl. Acad. Sci. U.S.A. 98
- Morris M. C., 1999, J. Biol. Chem., 274
- Müller B., 1989, J. Biol. Chem., 264
- Pace C. N., 1985, Methods Enzymol. 131, 266−280.
- Divita G., 1993, Biochemistry 32, 7966−7971.
- Wang J., 1994, Proc. Natl. Acad. Sci. U.S.A. 91
- Rodgers D. W., 1995, Proc. Natl. Acad. Sci. U.S.A. 92
- Hsiou Y., 1996, Structure 4, 853−860.
- Jacques P. S., 1994, J. Biol. Chem., 269
- Ren J., 2002, Proc. Natl. Acad. Sci. U.S.A. 99
- Sluis, 2003, Protein Sci. 12
Cited by
Survey of the year 2003 commercial optical biosensor literature
Rich, R. L., & Myszka, D. G. (2005) · Journal of Molecular Recognition · doi:10.1002/jmr.726 · Cited by 505
Survey of the year 2005 commercial optical biosensor literature
Rich, R. L., & Myszka, D. G. (2006) · Journal of Molecular Recognition · doi:10.1002/jmr.808 · Cited by 136
Camarasa, M.-J., Velázquez, S., San-Félix, A., Pérez-Pérez, M.-J., & Gago, F. (2006) · Antiviral Research · doi:10.1016/j.antiviral.2006.05.021 · Cited by 66
Allosteric modulation of protein oligomerization: an emerging approach to drug design
Gabizon, R., & Friedler, A. (2014) · Frontiers in Chemistry · doi:10.3389/fchem.2014.00009 · Cited by 67
“…from the oligomerization interfaces can inhibit the oligomerization and activity of such proteins, as was shown for the HIV-1 reverse transcriptase (Divita et al., 1994; Morris et al., 1999; Depollier et al., 2005) and integrase (Sourgen et al., 1996; Maroun et al., 2001; Zhao et al., 2003).”
BackgroundAgopian, A., Gros, E., Aldrian, G., Dereuddre‐Bosquet, N., Clayette, P., & Divita, G. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m802199200 · Cited by 33
Self-citationSmall Molecule Inhibitors Targeting HIV‐1 Reverse Transcriptase Dimerization
Grohmann, D., Corradi, V., Elbasyouny, M., Baude, A., Horenkamp, F. A., Laufer, S. D., Manetti, F., Botta, M., & Restle, T. (2008) · ChemBioChem · doi:10.1002/cbic.200700669 · Cited by 30
Self-citationPeptide Inhibition of HIV-1: Current Status and Future Potential
Kaushik‐Basu, N., Basu, A., & Harris, D. (2008) · BioDrugs · doi:10.2165/00063030-200822030-00003 · Cited by 28
Alcaro, S., Artese, A., Ceccherini‐Silberstein, F., Chiarella, V., Dimonte, S., Ortuso, F., & Perno, C. F. (2009) · Current Medicinal Chemistry · doi:10.2174/092986710790192695 · Cited by 25
Agopian, A., Depollier, J., Lionne, C., & Divita, G. (2007) · Journal of Molecular Biology · doi:10.1016/j.jmb.2007.07.044 · Cited by 23
Self-citationHomodimerization of the p51 Subunit of HIV-1 Reverse Transcriptase
Zheng, X., Mueller, G. A., Cuneo, M. J., DeRose, E. F., & London, R. E. (2010) · Biochemistry · doi:10.1021/bi902116z · Cited by 23
“Because drug-resistant strains of RT continue to evolve, the development of dimerization inhibitors has been an active area of research (7-14).”
Retroviral RNase H: structure, mechanism, and inhibition
(2021) · The Enzymes · doi:10.1016/bs.enz.2021.07.007 · Cited by 13
Pattyn, E., Lavens, D., der Heyden, J. V., Verhee, A., Lievens, S., Lemmens, I. H., Hallenberger, S., Jochmans, D., & Tavernier, J. H. (2008) · Journal of Virological Methods · doi:10.1016/j.jviromet.2008.06.021 · Cited by 16
Matamoros, T., Barrioluengo, V., Abia, D., & Menéndez‐Arias, L. (2013) · Biochemistry · doi:10.1021/bi401390x · Cited by 16
Sánchez‐Murcia, P. A., de Castro, S., Garcı́a-Aparicio, C., Jiménez, M. A., Corona, A., Tramontano, E., Sluis‐Cremer, N., Menéndez‐Arias, L., Velázquez, S., Gago, F., et al. (2020) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.9b00623 · Cited by 13
Gleenberg, I. O., Herschhorn, A., Goldgur, Y., & Hizi, A. (2006) · Archives of Biochemistry and Biophysics · doi:10.1016/j.abb.2006.12.007 · Cited by 14
Targeting human immunodeficiency virus type 1 assembly, maturation and budding.
Wapling, J., Srivastava, S., Shehu-Xhilaga, M., & Tachedjian, G. (2007) · Europe PMC (PubMed Central) · Cited by 11
Targeting Human Immunodeficiency Virus Type 1 Assembly, Maturation and Budding
Wapling, J., Srivastava, S., Shehu-Xhilaga, M., & Tachedjian, G. (2007) · Drug Target Insights · doi:10.1177/117739280700200020 · Cited by 12
“…designed to target the RT dimer interface in order to block HIV-1 RT function, including peptides corresponding to regions that are known to have an important role in RT dimerization (Debyser and De Clercq, 1996; Depollier et al. 2005; Divita et al. 1994; Morris et al. 1999b; Morris et al. 1999a).”
InfluentialUpadhyay, A. K., Pandey, N., Mishra, C. A., Talele, T. T., & Pandey, V. N. (2009) · Journal of Cellular Biochemistry · doi:10.1002/jcb.22439 · Cited by 8
“dimeric conformation of the enzyme [Depollier et al., 2005].”
BackgroundUpadhyay, A. K., Talele, T. T., & Pandey, V. N. (2009) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-009-0316-x · Cited by 6
“These authors have suggested that Gly substitution at positions 24 and 61 destabilizes the dimeric conformation of the enzyme, which may have affected the DNA binding function of the enzyme [40].”
BackgroundViral Protein Dimerization Quality Control: A Design Strategy for a Potential Viral Inhibitor
Du, S., Liu, X., Hu, X., & Zhan, P. (2024) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.4c01540 · Cited by 5
Xie, J. P., Zhang, P., Li, C., Huang, Q., Zhou, R., & Peng, T. (2011) · Gene · doi:10.1016/j.gene.2011.02.007 · Cited by 3
Relative domain orientation of the L289K HIV ‐1 reverse transcriptase monomer
Xi, Z., Ilina, T. V., Guerrero, M., Fan, L., Sluis‐Cremer, N., Wang, Y., & Ishima, R. (2022) · Protein Science · doi:10.1002/pro.4307 · Cited by 1
Analysis of the contact interfaces of HIV reverse transcriptase subunits
Belov, D. A., & Veselovsky, A. V. (2007) · Biochemistry (Moscow) Supplement Series B Biomedical Chemistry · doi:10.1134/s1990750807010027 · Cited by 1
Targeting Small Molecules and Peptides to the p66-p51 Reverse Transcriptase Interface
Moussa, D. A., Agopian, A., & Divita, G. (2013) · Springer eBooks · doi:10.1007/978-1-4614-7291-9_8
Self-citationSeetaha, S., Kamonsutthipaijit, N., Yagi‐Utsumi, M., Seako, Y., Yamaguchi, T., Hannongbua, S., Kato, K., & Choowongkomon, K. (2023) · The Protein Journal · doi:10.1007/s10930-023-10156-y
“Peptides derived from the connection domain of HIV-1 RT validate the dimerization of HIV-1 RT [11–13].”
MethodAbidi-Azzouz, N. (2013) · theses.fr (ABES) · doi:10.70675/c649b442z5a71z428dz9356z2a8d03796760
Metadata
- Authors
- Depollier, J., Hourdou, M.-L., Aldrian-Herrada, G., Rothwell, P., Restle, T., & Divita, G.
- Affiliations
- University of London (GB)
- Department of Molecular Biophysics & Therapeutics, Centre de Recherches de Biochimie Macromoléculaire, FRE-2593 CNRS, 1919 Route de Mende, 34293 Montpellier, France, School of Crystallography, Birbeck College, University of London, Malet Street, London WC1E 7HX, U.K., and Institut für Molekulare Medizin, UK S-H Campus of Lubeck, Ratzeburger Allee 160, 23538 Lübeck, Germany
- Corresponding author
- Divita, Gilles
- Venue
- Biochemistry
- Publisher
- American Chemical Society (ACS)
- Published
- 2005-01-20
- Volume
- 44
- Issue
- 6
- Pages
- 1909-1918
- ISSN
- 0006-2960 (ISSN-L)
- 1520-4995
- OpenAlex
- W2012928811
- Semantic Scholar
- 8e42c5110c99fb9fd20c1b5fc343f08d8ca684f2
- Cited by
- 28
- References
- 17
- Citations by year
- 2026: 1 · 2024: 1 · 2023: 1 · 2022: 1 · 2021: 1 · 2020: 1 · 2014: 1 · 2013: 3
- FWCI
- 2.57
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Biochemistry (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Infectious Diseases › HIV/AIDS drug development and treatment
- Life Sciences › Immunology and Microbiology › Virology › HIV Research and Treatment
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Structure and Dynamics
- Keywords
- HIV reverse transcriptase, enzyme dimerization, peptide inhibitors, binding sites, dimer dissociation, antiviral agents, HIV-1, HIV-2
- MeSH terms
- Amino Acid Sequence, Antiviral Agents, Enzyme Stability, Molecular Sequence Data, Oligopeptides, Phenylalanine, Protein Binding, Protein Conformation, Tryptophan, Viral Proteins, Mutagenesis, Site-Directed, Protein Structure, Tertiary, Dimerization, Anti-HIV Agents, Amino Acid Motifs, Protein Subunits, Protein Interaction Mapping, HIV Reverse Transcriptase
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.